Actively Recruiting
Pragmatic Geriatric Assessment Before Bispecific Antibody and CAR-T-Cell Therapy to Predict Toxicity and Outcomes in Older Patients
Led by University of Zurich · Updated on 2025-12-30
208
Participants Needed
2
Research Sites
8 weeks
Total Duration
On this page
Sponsors
U
University of Zurich
Lead Sponsor
U
University Hospital, Zürich
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the effects of CAR-T cell and bispecific antibody therapies in older adults aged 65 and above who have aggressive types of lymphoma or plasma cell diseases like multiple myeloma. These treatments are new and intense, with potential serious side effects, but little is known about how older patients tolerate them or what the long-term impacts are. The study aims to use simple clinical methods to assess everyday functions important to older adults, such as mobility and memory, to better predict treatment risks and side effects. The study involves a pragmatic geriatric assessment before patients undergo CAR-T or bispecific antibody therapies. This assessment focuses on areas like mobility, self-care, nutrition, and cognitive function to evaluate patients' fitness for these treatments. The goal is to see if these assessments can predict severe or lasting side effects and improve treatment planning for older patients. This observational study does not involve assigning specific treatments but monitors patients receiving these therapies as part of their care. During the study, participants will be evaluated from enrollment through three months after treatment ends for treatment toxicity and health-related quality of life. Researchers will use the assessments to monitor side effects and outcomes over time. The study also aims to develop a standardized screening process that could become routine before such therapies, potentially improving quality of life and reducing healthcare costs for older patients receiving these treatments.
CONDITIONS
Brief Title
Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients age 65 years or older
- Scheduled for CAR-T-cell or bispecific antibody treatments
- Signed informed consent
- Sufficient knowledge of the German or French language
You will not qualify if you...
- Inability to understand or sign informed consent
- Refusal to consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to enrollment
Participants undergo a pragmatic geriatric assessment before receiving CAR-T or bispecific antibody therapy.
1 visit (in-person)
Duration - From enrollment to 3 months after end of treatment
Participants are observed for treatment toxicity and health-related quality of life after therapy.
Visits as per treatment follow-up schedule
Trial Site Locations
Total: 2 locations
1
Inselspital Bern
Bern, Switzerland
Actively Recruiting
2
Universitätsspital Zürich
Zurich, Switzerland, 8091
Actively Recruiting
Research Team
W
Wiebke Rösler, Dr. med.
W
Wiebke Gagesch, PD Dr. med.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here